COVID-19 Protection After Transplant Pilot Study

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

81 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-10

Study Completion Date

2023-03-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Antibodies are an important part of the body's defense against infection. Individuals who have no antibodies or very low antibody levels are considered less well protected from Coronavirus Disease 2019 (COVID-19) than those who have higher antibody levels. What level of antibodies is necessary for protection is currently unknown.

Inadequate antibody response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination has been described among kidney transplant recipients. The aim of this study is to elicit an antibody response to vaccination against SARS-CoV-2 in kidney transplant recipients who have failed to respond to two doses of either the Moderna COVID-19 vaccine or Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) vaccine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

COVID Protection After Transplant-Immunosuppression Reduction

NCT05077254

Kidney Transplant Recipients Liver Transplant Recipients

COMPLETED PHASE2

Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients

NCT05220397

Kidney Transplant Recipient

TERMINATED PHASE3

Booster Dose of COVID-19 Vaccine for Kidney Transplant Recipients Without Adequate Humoral Response

NCT04961229

COVID-19 Acute Respiratory Distress Syndrome Immunosuppression

UNKNOWN PHASE4

COVID-19 3rd Dose Vaccine in Transplant Patients

NCT05047640

Covid19

TERMINATED PHASE3

Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients

NCT04885907

Vaccine Response Impaired Immune Suppression Covid19

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open label, non-randomized study in kidney transplant recipients who received two doses of either mRNA COVID-19 vaccine and have a negative (\<0.8 U/mL) or low (titer \<50 U/mL) SARS-CoV-2 antibody response using the Roche Elecsys® anti-RBD assay. Eligible participants will receive a third dose of the same mRNA vaccine as the prior two doses.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Transplant Recipients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Open label, non-randomized.

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BNT162b2 mRNA-based vaccine (Pfizer/BioNTech)

The BNT162b2 mRNA-based vaccine was developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. Kidney transplant recipients who had a suboptimal antibody response to the standard two doses of vaccination with Pfizer/BioNTech will receive a third dose of the the same vaccine.

Administration: One dose administered intramuscularly, upper arm.

Group Type EXPERIMENTAL

BNT162b2 vaccine (Pfizer/BioNTech)

Intervention Type BIOLOGICAL

30 microgram dose

mRNA-1273 vaccine (Moderna)

The mRNA-1273 vaccine was developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. Kidney transplant recipients who had a suboptimal antibody response to the standard two doses of vaccination with Moderna will receive a third dose of the same vaccine.

Administration: One dose administered intramuscularly, upper arm.

Group Type EXPERIMENTAL

mRNA-1273 vaccine (Moderna)

Intervention Type BIOLOGICAL

100 microgram dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BNT162b2 vaccine (Pfizer/BioNTech)

30 microgram dose

Intervention Type BIOLOGICAL

mRNA-1273 vaccine (Moderna)

100 microgram dose

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

COMIRNATY (COVID-19 vaccine, mRNA) SARS-CoV-2 mRNA vaccine Pfizer-BioNTech COVID-19 vaccine SARS-CoV-2 mRNA vaccine Moderna COVID-19 vaccine SPIKEVAX (COVID-19 vaccine, mRNA)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Individuals who meet all the following criteria are eligible for enrollment as study participants-

1. Able to understand and provide informed consent;
2. Recipient of kidney transplant ≥12 months prior to enrollment, without treated allograft rejection in the 6 months preceding enrollment;
3. Received 2 doses of either the Moderna COVID-19 vaccine or Pfizer-BioNTech COVID-19 vaccine as specified in the respective Food and Drug Administration Emergency Use Authorization (FDA EUAs), \>30 days and \<8 months prior to enrollment ; and,
4. Negative (antibody titer \< 0.8U/mL) or low (antibodies detected at titer ≤ 50 U/mL) response to the vaccine at \> 30 days from dose 2 of the Moderna COVID-19 vaccine or the Pfizer BioNTech vaccine, using the Roche Elecsys® anti-Receptor Binding Domain (RBD) assay.

Exclusion Criteria

Individuals who meet any of these criteria are not eligible for enrollment as study participants-

1. Recipient of any number of doses of any COVID vaccine product other than the Moderna COVID-19 vaccine or the Pfizer-BioNTech COVID-19 vaccine;
2. Known history of severe allergic reaction to any component of either the Moderna COVID-19 vaccine or Pfizer-BioNTech COVID-19 vaccine;
3. Thrombotic events, myocarditis, or pericarditis temporally associated with prior dose of COVID-19 vaccine;
4. Any change in transplant immunosuppression regimen (drug or dose) in response to suspected or proven rejection within the last 6 months;
5. Significant graft dysfunction;
6. Receipt of any cellular depleting agent (e.g. ATG, Rituximab, Alemtuzumab, Cyclophosphamide) within 12 months preceding enrollment;
7. Receiving systemic immunomodulatory medication(s) for any condition other than transplant;
8. Any untreated active infection, including BK viremia \>10\^4 copies;
9. Infection with human immunodeficiency virus (HIV);
10. Maintenance immunosuppressive regimen that includes belatacept or abatacept;
11. Recent (within one year) or ongoing treatment for malignancy; or
12. Any past or current medical problems, treatments, or findings which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the candidate's ability to comply with study requirements or may impact the quality or interpretation of the data obtained from the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No